The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Coronary interventions
Abluminal groove-filled biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent: three-year results of the TARGET All Comers trial
Yuichi Saito1, MD; Henning Kelbæk2, MD; Bo Xu3, MD; Yasin Hussain1, MD; Richard Anderson4, MD; Volker Schächinger5, MD; Ming Zheng6, MD; William Wijns7, MD; Andreas Baumbach1,8, MD; Alexandra J. Lansky1,8, MD
1. Yale University School of Medicine, New Haven, CT, USA; 2. Department of Cardiology, Roskilde University Hospital, Roskilde, Denmark; 3. Fu Wai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; 4. Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff, United Kingdom; 5. Medizinische Klinik I, Herz-Thorax Zentrum, Klinikum Fulda, Fulda, Germany; 6. Shanghai MicroPort Medical (Group) Co., Ltd., Shanghai, China; 7. The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway, and Saolta University Healthcare Group, Galway, Ireland; 8. Barts Heart Centre, London, and Queen Mary University of London, London, United Kingdom
Introduction
New-generation drug-eluting stents (DES), including both biodegradable and durable polymer stents, are currently recommended as a default strategy in percutaneous coronary intervention (PCI). A meta-analysis of 16 contemporary randomised DES trials demonstrated similar safety and efficacy of biodegradable polymer DES with respect to stent-related coronary events up to a mean follow-up period of 26 months compared to current-generation durable polymer DES, suggesting no clinical benefit of biodegradable polymer at least at two-year follow-up1. The Firehawk® (Shanghai MicroPort® Medical (Group), Co., Ltd., Shanghai, China) is a thin-strut coronary stent with sirolimus and biodegradable polymer complex localised in abluminal grooves ...
New-generation drug-eluting stents (DES), including both biodegradable and durable polymer stents, are currently recommended as a default strategy in percutaneous coronary intervention (PCI). A meta-analysis of 16 contemporary randomised DES trials demonstrated similar safety and efficacy of biodegradable polymer DES with respect to stent-related coronary events up to a mean follow-up period of 26 months compared to current-generation durable polymer DES, suggesting no clinical benefit of biodegradable polymer at least at two-year follow-up1. The Firehawk® (Shanghai MicroPort® Medical (Group), Co., Ltd., Shanghai, China) is a thin-strut coronary stent with sirolimus and biodegradable polymer complex localised in abluminal grooves ...
Sign in to read and download the full article
Forgot your password? No account yet?
Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Coronary interventionsSTEMINSTEMIStable CADStents and scaffolds
Read next article
Outcomes of transcatheter mitral valve repair for secondary mitral regurgitation by severity of left ventricular dysfunction
Latest news
NEW ISSUE
The Bifurcation ARC consensus; impact of P2Y12 de-escalation in HBR; 5-year outcomes of the TARGET trial and more...
December 4, 2023
STATE-OF-THE-ART
Free access collection all year long
December 4, 2023
AHEAD OF PRINT
Poor improvement of post-PCI iFR in LAD
FREE ARTICLE - Mitsuaki Matsumura et al
November 30, 2023
AHEAD OF PRINT
Robotic-assisted CABG: clinical outcomes
FREE ARTICLE - Aleksander Dokollari et al
November 23, 2023
AHEAD OF PRINT
Pathophysiological CAD patterns predict outcomes post-PCI
FREE ARTICLE - Nozomi Kotoku et al
November 14, 2023
PCR London Valves 2023
November 16, 2023
AHEAD OF PRINT
Extra-mitral valve cardiac involvement in MR
FREE ARTICLE - Antonio Popolo Rubbio et al
November 9, 2023